<DOC>
	<DOCNO>NCT01031628</DOCNO>
	<brief_summary>The purpose study determine escalate dose imatinib keep drug blood level ≥ 1100 ng/ml lead good outcomes patient .</brief_summary>
	<brief_title>Study Dose Escalation Versus Dose Escalation Imatinib Metastatic Gastrointestinal Stromal Tumors ( GIST ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age ≥ 18 year Unresectable and/or metastatic GIST Currently receive imatinib 400 mg per day minimum 4 week prior registration , 6 month prior registration . This must first time patient treat metastatic and/or unresectable GIST For patient receive imatinib follow surgery time initial diagnosis GIST , must 6 month interval completion imatinib diagnosis metastatic GIST Good physical functioning ( ECOG Performance Status 0 1 ) Generally , good function organ liver kidney Disease progression adjuvant therapy imatinib ( adjuvant treatment treatment give surgery GIST ) Known intolerance imatinib dose 400 mg/day high Prior systemic therapy advance GIST imatinib imatinib longer 6 month unresectable and/or metastatic disease Major surgery within 2 week prior Day 1 study yet recover prior surgery Use coumadin derivative ( i.e . warfarin , acenocoumarol , phenprocoumon ) Patients receive wide field radiotherapy ≤ 4 week limited field radiation palliation &lt; 2 week recover side effect therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>GIST</keyword>
	<keyword>Gastrointestinal stromal tumor</keyword>
	<keyword>Exon 9</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Imatinib blood level</keyword>
</DOC>